Healthcare Industry News: Terumo
News Release - January 11, 2006
Terumo Medical Corporation Names John Rooney Vice President of Marketing for Terumo Interventional SystemsRooney to oversee expansion of marketing and the inside sales and service teams as Terumo parts ways with Boston Scientific on interventional business
SOMERSET, N.J., Jan. 11 (HSMN NewsFeed) -- Terumo Medical Corporation -- a business unit of global device manufacturer Terumo Corp. -- today announced the appointment of John Rooney to Vice President of Marketing, Terumo Interventional Systems.
Rooney, a veteran of the medical device industry, will assume responsibilities for distribution and promotion of Terumo Medical Corporation's embolotherapy line, the Glide family of interventional wires and catheters, and the Pinnacle line of introducer sheaths, which have become deeply entrenched in use by interventional specialists including interventional radiologists, interventional cardiologists, interventional neuroradiologists and vascular surgeons. Terumo Medical Corporation has supplied these products to the U.S. marketplace over the past 18 years.
Rooney has held positions of increased responsibility in sales, operations and marketing departments in the medical devices, diagnostics and pharmaceutical field. Rooney was most recently Director of Marketing at Roche Diagnostics, responsible for the Direct to Professional promotion of the Accu-Chek brand of self monitoring blood glucose products, the largest single brand in Hoffman LaRoche worldwide. In this role, he managed the promotion to all physicians, nurses, educators and pharmacists in the U.S. marketplace for Roche Diagnostics and the Accu-Chek products.
"John brings a wealth of strategic marketing and sales experience and an aggressive style to our marketing efforts at TIS -- a task exponentially more important as we launch our own distribution and marketing strategy in the interventional space," said Jim Rushworth, Vice President and General Manager, Terumo Interventional Systems. "We have been delivering interventional medical devices to thousands of hospitals and physicians for the past 18 years and John's background in marketing and experience in sales will enable him to strategically link all of the current operational systems we have in place as we go direct come April 1, 2006."
Rooney is playing a key role in the expansion of Terumo's Marketing capability, sales force, and customer service capabilities as it takes back distribution of its interventional products including Glidewire® guidewires, Glidecath® catheters and Pinnacle® introducer sheaths. Effective April 1, 2006, Terumo Medical Corporation is ending a 15-year relationship with Boston Scientific through which Boston Scientific provided marketing, sales and distribution of Terumo's vascular interventional products. Terumo has expanded its sales and marketing teams over the past year and a half from six to approximately 80 people.
"This is a great opportunity to advance Terumo's strategy to get closer to the specialists that use its devices," Rooney said. "Terumo is well known within the medical community for its outstanding quality in entry site management and lesion access products. By going direct in April 2006, we will begin to fulfill Terumo's vision to have TIS become a leading endovascular company. We are not coming to market simply to promote these existing brands but to enhance Terumo's ability to deliver new interventional technologies focused upon the improvement of patient outcomes. Terumo has been behind the quality and success of the products Boston Scientific has distributed for us since their introduction in 1987 and now we need to improve these products more than ever before to demonstrate our commitment to the continuum of care and become a strong endovascular company."
Terumo Medical Corporation -- Clinical Excellence in an Expanding
Founded in 1972, Terumo Medical Corporation (TMC) develops, manufactures and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. Terumo Medical manufactures high quality needles and syringes, entry site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide. Terumo Interventional Systems, a business unit of TMC, sells a full line of guidewires, catheters, introducer sheaths, and embolization products for use in a multitude of different interventional procedures. Interventional radiologists, interventional neuroradiologists, interventional cardiologists and vascular surgeons are among the medical professionals that depend upon TIS products to access and cross difficult to reach lesions thereby allowing therapeutic intervention in previously unreachable vascular beds.
ABOUT Terumo CORPORATION.
Terumo Medical Corporation is the U.S. subsidiary of Tokyo-based Terumo Corporation, one of the world's leading medical device companies, with $2.3 billion in sales and operations in more than 150 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufacturers a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543:JP) and is a component of the Nikkei 225, Japan's leading stock index.
Source: Terumo Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.